Squarepoint
ADMS

Squarepoint’s Adamas Pharmaceuticals ADMS Stock Holding History

Squarepoint’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,561
Closed -$93K – 3723
2021
Q2 		$93K Sell
17,561
-39,923
-69% -$207K ﹤0.01% 3030
2021
Q1 		$276K Buy
57,484
+17,662
+44% +$92.2K ﹤0.01% 2469
2020
Q4 		$172K Sell
39,822
-42,541
-52% -$182K ﹤0.01% 2567
2020
Q3 		$339K Buy
82,363
+72,336
+721% +$280K ﹤0.01% 1713
2020
Q2 		$26K Buy
+10,027
New +$29.5K ﹤0.01% 2146
2020
Q1 		– Sell
-30,177
Closed -$114K – 2771
2019
Q4 		$114K Buy
+30,177
New +$144K ﹤0.01% 2328
2019
Q3 		– Sell
-19,803
Closed -$123K – 2798
2019
Q2 		$123K Buy
+19,803
New +$114K ﹤0.01% 2198
2019
Q1 		– Sell
-24,720
Closed -$211K – 2542
2018
Q4 		$211K Sell
24,720
-27,680
-53% -$360K ﹤0.01% 1664
2018
Q3 		$1.05M Sell
52,400
-77,474
-60% -$1.82M 0.01% 965
2018
Q2 		$3.35M Buy
129,874
+94,882
+271% +$2.63M 0.04% 490
2018
Q1 		$836K Buy
34,992
+12,164
+53% +$384K 0.01% 872
2017
Q4 		$774K Buy
22,828
+11,532
+102% +$322K 0.01% 951
2017
Q3 		$239K Buy
+11,296
New +$207K ﹤0.01% 1292

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's ADMS Position: Q3 2021 in Review

Squarepoint sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 17,561 shares — an estimated $93K sold.

Squarepoint first reported a position in ADMS in Q3 2017 and held it in 13 quarters. The position peaked at $3.35M in Q2 2018. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Squarepoint reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 17,561 Adamas Pharmaceuticals shares in Q3 2021, an estimated $93K.
  • Squarepoint first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 13 quarters.
  • Squarepoint's Adamas Pharmaceuticals position peaked at $3.35M in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.